Janin Nouhin

Janin Nouhin

Auto-generated profile, based on publicly available information

Janin Nouhin

Virology Unit, Institut Pasteur du Cambodge Pasteur Network Phnom Penh Cambodia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
KTKaiming Tao
Kaiming Tao
PTPhilip L. Tzou
Philip L. Tzou
JNJanin Nouhin
Janin Nouhin
RGRavindra K. Gupta
Ravindra K. Gupta
TOTulio de Oliveira
Tulio de Oliveira
Robert W ShaferRobert W Shafer
Robert W Shafer

1 November 2007 in Pediatrics
Verified
Journal Article
Closed access
BJBart Janssens
Bart Janssens
BRBrian Raleigh
Brian Raleigh
SSSeithaboth Soeung
Seithaboth Soeung
KAKazumi Akao
Kazumi Akao
VTVantha Te
Vantha Te
ENEric Nerrienet
Eric Nerrienet
OBJECTIVE. Increasing access to highly active antiretroviral therapy to reach all those in need in developing countries (scale up) is slowly expanding to HIV-positive children, but documented experience remains limited. We aimed to describe the clinical, immunologic, and virologic outcomes of pediatric patients with >12 months of highly active antiretroviral therapy in 2 routine programs in Cambodia. METHODS. Between June 2003 and March 2005, 212 children who were younger than 13 years started highly active antiretroviral therapy. Most patients started a standard first-line regimen of lamivudine, stavudine, and nevirapine, using split adult fixed-dosage combinations. CD4 percentage and body weight were monitored routinely. A cross-sectional virologic analysis was conducted in January 2006; genotype resistance testing was performed for patients with a detectable viral load. RESULTS. Mean age of the subjects was 6 years. Median CD4 percentage at baseline was 6. Survival was 92% at 12 months and 91% at 24 months; 13 patients died, and 4 were lost to follow-up. A total of 81% of all patients had an undetectable viral load. Among the patients with a detectable viral load, most mutations were associated with resistance to lamivudine and non–nucleoside reverse-transcriptase inhibitor drugs. Five patients had developed extensive antiretroviral resistance. Being an orphan was found to be a predictor of virologic failure. CONCLUSIONS. This study provides additional evidence of the effectiveness of integrating HIV/AIDS care with highly active antiretroviral therapy for children in a routine setting, with good virologic suppression and immunologic recovery achieved by using split adult fixed-dosage combinations. Viral load monitoring and HIV genotyping are valuable tools for the clinical follow-up of the patients. Orphans should receive careful follow-up and extra support.

9 September 2020 in Viruses
Verified
Journal Article
Open access
PDF file
PTPhilip Tzou
Philip Tzou
KTKaiming Tao
Kaiming Tao
JNJanin Nouhin
Janin Nouhin
SRSoo-Yon Rhee
Soo-Yon Rhee
BHBenjamin D Hu
Benjamin D Hu
Robert W ShaferRobert W Shafer
Robert W Shafer
Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database. Results: As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. Conclusion: CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development.

1 August 2006 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
MNMarie Nguyen
Marie Nguyen
PPPolidy Pean
Polidy Pean
Lucia LopalcoLucia Lopalco
Lucia Lopalco
JNJanin Eng Nouhin
Janin Eng Nouhin
VPViseth Phoung
Viseth Phoung
GPGianfranco Pancino
Gianfranco Pancino
Summary: To study biological factors related to protection against HIV-1 infection in Cambodia, we recruited 48 partners of HIV-1-infected patients who remained uninfected (exposed uninfected individuals, EUs) despite unprotected sexual intercourse for more than 1 year and 49 unexposed controls (UCs). HIV-1-specific antibodies (IgA anti-gp41 and IgG anti-CD4-gp120 complex), T-cell responses, and cellular factors that may be involved in protection (peripheral blood mononuclear cell [PBMC] resistance to HIV-1 infection and β-chemokine production) were evaluated. Anti-HIV-1 antibodies were higher in EUs than those in UCs (P = 0.01 and P = 0.04 for anti-gp41 and anti-CD4-gp120, respectively). We observed a decreased susceptibility to a primary Cambodian isolate, HIV-1KH019, in EU PBMCs as compared with UC PBMCs (P = 0.03). A weak T-cell response to one pool of HIV-1 Gag peptides was found by ELISpot in 1 of 19 EUs. Whereas T-cell specific immunity was not associated to protection, our results suggest that HIV-specific humoral immunity and reduced cell susceptibility to infection may contribute to protection against HIV-1 infection in Cambodian EUs.

1 January 2011 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
LFLaurent Ferradini
Laurent Ferradini
VOVara Ouk
Vara Ouk
OSOlivier Segeral
Olivier Segeral
JNJanin Nouhin
Janin Nouhin
ADAnne Dulioust
Anne Dulioust
ENEric Nerrienet
Eric Nerrienet
Background: The number of patients on second‐line highly active antiretroviral therapy (HAART) regimens is increasing in resource‐limited settings. We describe the outcomes after 24 months for patients on LPV/r‐based second‐line regimens followed up by the ESTHER programme in Phnom Penh, Cambodia.Methods: Seventy patients who initiated second‐line HAART regimens more than 24 months earlier were included, and immuno‐virological data analyzed. HIV RNA viral load was determined by real‐time RT‐PCR. HIV‐1 drug resistance was interpreted according to the ANRS algorithm.Results: Of the 70 patients, two were lost to follow up, three died and 65 (92.8%) remained on second‐line treatment after 24 months of follow up (median duration of treatment: 27.4 months). At switch to second‐line, the median CD4 T cell count was 106 cells/mm3 and the median viral load was 4.7 Log10. Second‐line regimens prescribed were ddI/3TC/LPV/r (65.7%), ddI/TDF/LPV/r (10.0%), ddI/AZT/LPV/r (8.6%) and TDF/3TC/LPV/r (7.1%). The median CD4 T cell gain was +258 cells/mm3 at 24 months (n = 63). After 24 months of follow up, 92.3% (60/65) of the patients presented undetectable viral loads, giving an overall treatment success rate of 85.7% (CI: 75.6‐ 92.0) in intent‐to‐treat analysis.Conclusions: These data suggest that a LPV/r‐based second‐line regimen is associated with a high rate of virological suppression and immune reconstitution after 24 months of follow up in Cambodia.

1 November 2009 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
AAAhidjo Ayouba
Ahidjo Ayouba
TLTruong T.X. Lien
Truong T.X. Lien
JNJanin Nouhin
Janin Nouhin
LVLaurence Vergne
Laurence Vergne
Avelin F. AghokengAvelin F. Aghokeng
Avelin F. Aghokeng
MCMarie-Laure Chaix
Marie-Laure Chaix
The frequency of transmitted HIV drug resistance (HIVDR) was evaluated in the context of rapid scale-up of antiretroviral treatment in Thailand, Vietnam, Burkina Faso, Côte d'Ivoire, and Senegal by using an adaptation of the WHO generic protocol of the HIV Drug Resistance Threshold Survey (HIVDR-TS) for sample collection and classification. Resistance-associated mutations were interpreted using the 2009 WHO list for epidemiological surveys. We included 266 subjects from the five study sites. Of the 266 RT and PR sequences analyzed, two from Vietnam harbored virus with major drug resistance mutations (G190A in RT for one individual and M46I in PR for the second individual). Phylogenetic analysis revealed that CRF01_AE predominates (>90%) in Thailand and Vietnam. CRF02 (>65%) cocirculates with other HIV-1 variants in Senegal and Côte d'Ivoire. The prevalence of HIVDRM is scored as low (≤5%) in all the five sites for the three drug classes analyzed. A continuous population survey for HIVDRM will provide a rational basis for maintaining or changing the current first line regimen in these countries.